Salix may be a suitor for Furiex; Rivals chase GSK in asthma;

@FierceBiotech: AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project. More | Follow @FierceBiotech

@JohnCFierce: Upbeat review of failed PhII DMD trial earns Prosensa a big boost to shares. News | Follow @JohnCFierce

@DamianFierce: A quarter of European doctors can't define biosimilars. Story via Bloomberg. | Follow @DamianFierce

@EmilyMFierce: Snails and quails in today's issue of FierceBiotech Research. | Follow @EmilyMFierce

> Salix Pharmaceuticals ($SLXP) could be taking a close look at noted M&A target Furiex Pharmaceuticals ($FURX), Bloomberg reports. News

> GlaxoSmithKline ($GSK) leads the way in the race to cash in on the next generation of asthma treatments, but rivals including Roche ($RHHBY), AstraZeneca ($AZN) and Sanofi ($SNY) are gaining ground. Article

> The rise of biosimilars may be slower than many expect: According to a survey, about 25% of European doctors couldn't define or hadn't heard of copies of biologic treatments. Item

Medical Device News

@FierceMedDev: Teleflex's vascular system gains pivotal FDA clearance--the product comes from a previous M&A deal. More | Follow @FierceMedDev

@MarkHFierce: Mela Sciences' 2013 financials show how tough a relaunch of its skin cancer Dx tool will be. Story | Follow @MarkHFierce

@MichaelGFierce: SynapDx, Broad Institute align to make autism Dx with next-gen sequencing. Item | Follow @MichaelGFierce

@EmilyWFierce: Evidence of world's oldest case of metastatic cancer found in a skeleton in the Sudan. Article | Follow @EmilyWFierce

> OrbiMed backs an Israeli startup developing a futuristic, handheld diagnostic device. News

> St. Jude Medical will test its leadless pacemaker in a massive EU post-marketing trial. Story

> FDA puts the brakes on Avedro with complete response letter on KXL System. More

Pharma News

@FiercePharma: Best-read special report over the weekend: Top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> Pfizer sues India's Torrent in latest bid to fend off generic Viagra. News

> Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales. More

> New incontinence data could give Ipsen's Dysport a path to lucrative urology use. Story

Biotech Research News

> Capturing leukemic stem cells may help propel new drug discovery. More

> Study: Chickens, quails are likely to blame for spread of H7N9. Piece

> Drug derived from snail venom could treat chronic pain with fewer side effects. Article

> Compound stops formation of toxic peptides in mice with Alzheimer's. More

> NIH cuts, sequestration hampering cancer research. Story

> Stem cell therapy improves tendon healing in preclinical study. Item

Pharma Manufacturing News

> Japan's Eisai intends to nearly triple production to 2 billion tablets at its plant in Vizag, India. Report

> The FDA has added two Chinese drug manufacturing facilities to its list of banned plants. Alerts

> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. Report

> Ranbaxy Laboratories insists the drugs it sells in India are safe and effective. Story

> Optel Visions is expanding its inspection systems offerings. Release

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.